Our investment portfolio includes companies passionate about the development and commercialization of innovative products and platform technologies for the prevention, diagnosis and treatment of significant diseases.
Covagen develops next generation protein drugs for the treatment of inflammatory diseases and cancer by using its proprietary protein engineering technology, which has been developed at ETH Zurich. Covagen's innovative platform comprises the recently developed Covalent DNA Display technology and a novel single domain protein scaffold, which – in analogy to antibodies – can be engineered to yield high affinity binding proteins called Fynomers that can be used for therapeutic applications. In addition, the modular structure of Covagen's Fynomers and their favorable biophysical properties potentially allow for treatment modalities that are difficult or impossible to be exploited with antibodies. MPH participated in Covagen’s seed financing round in October 2009. For more information, please visit www.covagen.com.
f-star is a biotherapeutics platform company developing next generation antibodies (Ab) and Ab fragments. Their core technology allows the introduction of antigen binding sites into non-CDR loops of Abs, enabling high affinity target binding by Fc fragments or the addition of new binding sites into full length Abs to create bi-specific molecules. f-star is located in Vienna, Austria and Cambridge, UK. MPH participated in f-star’s Extended Series A financing round in January 2010. For more information, please visit www.f-star.com.
GenKyoTex is a leader in the development of novel therapeutics targeting Nicotinamide-adenine dinucleotide phosphate (NADPH) oxidases, also called NOX enzymes. GenKyoTex has developed a unique screening platform to identify selective, first in class, novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. These include diabetes, cardiovascular, neurodegenerative and pulmonary diseases. The lead compound, GKT137831, is a selective NOX1/4 inhibitor that will enter Phase 1 trials later in 2011 and is targeted for the treatment of diabetic nephropathy. MPH participated in the Series C financing round in May 2011. For more information please visit www.genkyotex.com.
Genocea Biosciences is developing novel vaccines against various infectious diseases using its proprietary platform for the rapid discovery of T-cell antigens. Its lead programs include HSV2, Streptococcus pneumoniae, and Chlamydia trachomatis. MPH participated in Genocea's Series B financing round in January 2011. For more information, please visit www.genocea.com.
PharmEste S.r.l. is developing its proprietary small molecule TRPV1 (transient receptor potential vanilloid 1) antagonists for the treatment of neuropathic pain, overactive bladder and other sensory neuron-mediated diseases. Their lead project is in phase I clinical testing. Pharmeste is located in Ferrara and Milan, Italy. MPH participated in Pharmeste’s Series B financing round in October 2008. For more information, please visit www.pharmeste.com.
Pronota NV is a Belgian diagnostics company with two cutting-edge technologies for low abundance protein biomarker discovery and antibody-free, multiple protein assay development. The company has biomarker candidates for preeclampsia,and other programs in cardio-renal disease and ovarian cancer are in progress. MPH participated in Pronota’s Series B financing round in October 2009. For more information, please visit www.pronota.com.
Syndexa is developing novel drugs targeting the interface between inflammatory and metabolic pathways. With its proprietary screening technologies targeting ER adaptive responses, Syndexa has identified lead molecules for the treatment of various diseases including type 2 diabetes, obesity and cardiovascular disease. Syndexa is based in Watertown, MA. MPH participated in Syndexa's Series B1 financing round in January, 2012. For more information, please visit www.syndexa.com.
Thrasos Therapeutics is a clinical-stage biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The company is advancing therapeutic programs, led by THR-184, for renal diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). MPH participated in Thrasos’ Series C financing round in October 2012. For more information, please visit www.thrasos.com.